Wall Street brokerages expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to announce $25.88 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $25.83 million and the highest is $25.90 million. Oxford Immunotec Global posted sales of $23.71 million in the same quarter last year, which suggests a positive year over year growth rate of 9.2%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full-year sales of $25.88 million for the current fiscal year, with estimates ranging from $103.84 million to $104.70 million. For the next year, analysts forecast that the firm will report sales of $119.34 million per share, with estimates ranging from $117.90 million to $120.66 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Oxford Immunotec Global.
Several research firms recently issued reports on OXFD. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the company a “buy” rating in a research note on Monday, December 18th. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Robert W. Baird restated a “buy” rating and set a $20.00 price target on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. Finally, ValuEngine cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.75.
Several institutional investors and hedge funds have recently modified their holdings of the company. Redmile Group LLC boosted its position in shares of Oxford Immunotec Global by 7.5% in the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after purchasing an additional 151,100 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in shares of Oxford Immunotec Global by 44.0% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock worth $22,773,000 after purchasing an additional 413,904 shares in the last quarter. RTW Investments LP boosted its position in shares of Oxford Immunotec Global by 21.9% in the 3rd quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock worth $17,344,000 after purchasing an additional 185,453 shares in the last quarter. Wasatch Advisors Inc. boosted its position in shares of Oxford Immunotec Global by 35.5% in the 3rd quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after purchasing an additional 150,343 shares in the last quarter. Finally, Cortina Asset Management LLC boosted its position in shares of Oxford Immunotec Global by 12.8% in the 3rd quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock worth $9,463,000 after purchasing an additional 63,765 shares in the last quarter. 89.35% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Oxford Immunotec Global (OXFD) opened at $14.06 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. Oxford Immunotec Global has a 52-week low of $12.19 and a 52-week high of $19.51. The stock has a market capitalization of $357.37, a price-to-earnings ratio of -6.96 and a beta of -0.09.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.